Biowatch

Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter, but their bottom lines diverged...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
Yuhan Ramps Up OTC Magnesium Push with Dual-Campaign for Liquid and High-Dose 'MagV'

Yuhan Ramps Up OTC Magnesium Push with Dual-Campaign for Liquid and High-Dose 'MagV'

If your lower eyelid twitches or you experience sudden leg cramps, it is common to assume a magnesium deficiency is to...
Jung Yoo-seok Becomes Ilyang Pharmaceutical’s Largest Shareholder, Completing Third-Generation Succession

Jung Yoo-seok Becomes Ilyang Pharmaceutical’s Largest Shareholder, Completing Third-Generation Succession

Ilyang Pharmaceutical’s largest shareholder position has shifted from Chairman Jung Do-eon to his eldest son, CEO and...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
Sales Rise 11%, but Chong Kun Dang’s Q2 Operating Profit Slips 10%

Sales Rise 11%, but Chong Kun Dang’s Q2 Operating Profit Slips 10%

Chong Kun Dang posted higher sales in the second quarter of this year, but its operating profit fell 10% from a year...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...